SHAH ALAM, Malaysia, Dec. 30, 2024 /PRNewswire/ -- While gender parity has seen progress in recent years, the women's health gap remains significant. Women, despite comprising half of the global labor force[1], often face under-diagnosis and under-representation in healthcare research. Biotropics Malaysia is addressing this disparity by advancing clinical studies led by women, focused on health areas that have been drawn up as top priority to close the women's health gap.
1.Cardiovascular Health
Cardiovascular disease (CVD) is the leading cause of death in women, with risks increasing after menopause due to hormonal changes. Biotropics' Nu-Femme® and SLP+® have been clinically validated[2] to support cardiovascular health, showing improvements in lipid profiles and reductions in 8-isoprostane, a marker of CVD. These ingredients are derived from Kacip Fatimah (Labisia pumila), a traditional Malaysian herb known for supporting feminine vitality.
Natural solutions for menstrual and menopausal health are increasingly sought after by women for mental clarity, emotional stability, physical health and overall well-being. Clinical studies[3] revealed that daily supplementation with SLP+® (200-400mg) enhances overall quality of life, while Nu-Femme® (500mg) reduces severe hot flashes by 73%, joint pain by 68%, and improves vitality by 21%. Biomarker studies further show that Nu-Femme® regulates hormonal imbalances by reducing FSH and LH levels (normally elevated in women experiencing estrogen decline during menopause) and supporting healthy testosterone and estradiol levels.
For women with 'brain fog' or menopausal disturbance affecting mood and negative feeling, BioKesum® (persicaria minor) offers a comprehensive approach, targeting multiple aspects of mental, mood & cognitive wellness. 500 mg daily showed improvement in cognitive flexibility, executive function and IQ performance, positive shifts in brain markers and reduction in tension, depression and anger[4].
Looking ahead, Biotropics Malaysia is excited to launch Physta® Tongkat Ali for women's health in 2025. Visit us at the Functional Food for Wellness Summit 2025 in Bangkok (Booth A5) for insights into women's health and our innovations. For details, contact marketing@biotropicsmalaysia.com or visit www.biotropicsmalaysia.com.
[1] Our World in Data, March 2024. "Women's Employment - How does women's labor force participation differ across countries? How has it changed over time? What is behind these differences and changes?". https://ourworldindata.org/female-labor-supply
[2] Mohd Noor, N., et. al. 2014. Efficacy and Safety of Labisia pumila var alata Water Extract Among Pre- and Postmenopausal Women. Journal of Medicinal Food: 17(8), pp. 1-10
[3] Chinnappan, et. al, 2020. Efficacy of Labisia pumila and Eurycoma longifolia standardized extracts on hot flushes, quality of life, hormone and lipid profile of peri-menopausal and menopausal women: randomized, placebo-controlled study. Food & Nutrition Research 2020: 10.29219/fnr.v64.3665
[4] Lau, H., Shahar, S., Mohamad, M., Rajab, N. F., Yahya, H. M., Che Din, N. and Abdul Hamid, H., 2020. The effects of six months Persicaria minor extract supplement among older adults with mild cognitive impairment: a double-blinded, randomized, placebo-controlled trial. BMB Complementary Medicine and Therapies 20:315.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
"Closing the Women's Health Gap - Highlights of Biotropics Malaysia clinical study by Women, on Women, for Women"
HONG KONG, Jan. 2, 2025 /PRNewswire/ -- HKSH Cancer Centre organised the sixth "HKSH Symposium on Advances in Cancer Management" ("The Symposium") which was held on 12 December 2024 at the HKSH Eastern Building. With the theme "Breakthroughs in Cancer Management", the Symposium attracted approximately 800 healthcare professionals from around the globe to participate both in-person and online. As the HKSH Proton Therapy Centre marks its one-year anniversary, being one of over 120 proton therapy facilities worldwide, several experts from HKSH focused on sharing local experiences with Hong Kong's first proton therapy system in treating major cancers such as head and neck cancer, breast cancer, and paediatric cancer. They also explored groundbreaking advancements combining clinical and research cancer treatments, including MR-guided radiotherapy, genomic profiling in cancer for precision medicine, and latest advances in medical therapy for cancers.
Dr. Walton LI, Chief Executive Officer of the HKSH Medical Group ("HKSH") and Medical Superintendent of Hong Kong Sanatorium & Hospital, highlighted in his opening speech, "After nearly two decades of efforts for the proton therapy project, Hong Kong's first proton therapy system officially commenced service in 2023, marking a significant breakthrough in medical technology for Hong Kong, thanks to the concerted efforts of multiple specialty teams. We hope the Symposium provides a platform for experts from different fields to exchange experiences and new knowledge, thereby striving to improve clinical outcomes in cancer treatment." Dr. LI also mentioned that besides providing clinical services and advancing research, HKSH has been collaborating with the Mayo Clinic in Arizona, USA, to offer specialised proton therapy training for oncology specialists, further establishing Hong Kong's role as a cancer medical hub in the Greater China region.
Mr. Wyman LI, Chief Operating Officer of HKSH Medical Group and Director of Hong Kong Sanatorium & Hospital, emphasised in the closing, "With the opening of the HKSH Proton Therapy Centre, HKSH is now equipped with a full range of world-class advanced cancer radiotherapy systems. Our team has carried out approximately 300 proton therapy cases to date, mainly comprising breast cancer and prostate cancer cases, with paediatric patients making up about ten percent. HKSH will continue to steadily develop proton therapy services to implement treatment plans for major cancers, especially focusing on the needs of paediatric cancer patients to minimise treatment side effects and assist in their healthy growth."
HKSH Cancer Centre, following the launch of proton therapy services, is steadily advancing into a new milestone. Now run on Happy Valley and A Kung Ngam campuses, HKSH Cancer Centre will continue to strive for the best experience for our patients throughout the patient journey with multidisciplinary services, ranging from cancer genetics, diagnostics, rehabilitation to counselling to offer high-quality and reliable medical options and services to cancer patients. Looking ahead, HKSH will host the fifth PTCOG Asia Oceania Congress in November 2025, marking the first international particle therapy academic meeting held in Hong Kong. It is anticipated to attract top global experts to explore innovative treatments, further promote and enhance healthcare standards, and bring hope for treatment to cancer patients.
For more information:
Learn more about HKSH Proton Therapy Centre here
Watch our Proton Therapy video series here
For enquiries, please contact:
Corporate Affairs Department, HKSH Medical Group
media@cad.hksh.com
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
HKSH Symposium on Advances in Cancer Management 2024 Breakthroughs in Cancer Management
